Ewing's Family of Tumors
Welcome,         Profile    Billing    Logout  
 49 Companies   54 Products   54 Products   60 Mechanisms of Action   1 Trial   194 News 


1234»
  • ||||||||||  cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Surgery:  GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) -  Aug 1, 2018   
    P2,  N=43, Completed, 
    Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision. Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018 | Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  cyclophosphamide / Generic mfg.
    Trial completion:  Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma (clinicaltrials.gov) -  Jun 15, 2018   
    P1/2,  N=44, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018 | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
  • ||||||||||  Seprehvir (HSV1716) / Sorrento
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) -  Mar 21, 2018   
    P1,  N=18, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=30 --> 18 | Trial completion date: Jul 2018 --> Mar 2018 | Trial primary completion date: Jul 2018 --> Mar 2018
  • ||||||||||  Phase classification, Trial primary completion date:  Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) -  Oct 6, 2017   
    P2,  N=8, Terminated, 
    Trial primary completion date: Dec 2017 --> Jul 2018 Phase classification: P1/2 --> P2 | Trial primary completion date: Jun 2015 --> May 2014
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Trial completion, Trial initiation date, Trial primary completion date, Metastases:  Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) -  Jun 14, 2017   
    P2,  N=40, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
  • ||||||||||  dactinomycin / Generic mfg., vincristine / Generic mfg.
    Biomarker, Trial completion, Trial primary completion date:  Evaluating Dactinomycin and Vincristine in Young Patients With Cancer (clinicaltrials.gov) -  May 17, 2017   
    P=N/A,  N=158, Completed, 
    Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jun 2016
  • ||||||||||  Trial completion:  High-dose ICE With Amifostine (clinicaltrials.gov) -  Jan 23, 2017   
    P2,  N=24, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
  • ||||||||||  Biomarker, Trial completion, Trial primary completion date:  Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) -  Jul 14, 2016   
    P=N/A,  N=1650, Completed, 
    Recruiting --> Active, not recruiting | N=75 --> 50 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
  • ||||||||||  Biomarker, Trial completion, Trial primary completion date:  Biomarker in Tissue Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) -  Jul 12, 2016   
    P=N/A,  N=40, Completed, 
    Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
  • ||||||||||  Trial completion, Trial primary completion date:  Study of Tumor Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) -  May 19, 2016   
    P=N/A,  N=200, Completed, 
    Recruiting --> Completed | N=35 --> 27 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
  • ||||||||||  Trial completion, Enrollment change:  Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (clinicaltrials.gov) -  Apr 28, 2016   
    P=N/A,  N=950, Completed, 
    N=24 --> 6 | Recruiting --> Terminated; Slow accrual and lack of funding Recruiting --> Completed | N=2200 --> 950
  • ||||||||||  Trial termination:  Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) -  Mar 16, 2016   
    P1/2,  N=8, Terminated, 
    Recruiting --> Completed | N=2200 --> 950 Completed --> Terminated; Study was closed to enrollment before dose level one was completed.
  • ||||||||||  Talzenna (talazoparib) / Pfizer
    Enrollment change, Trial primary completion date, Metastases:  Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) -  Mar 10, 2016   
    P1,  N=74, Active, not recruiting, 
    Completed --> Terminated; Study was closed to enrollment before dose level one was completed. N=113 --> 74 | Trial primary completion date: Jan 2016 --> Mar 2015
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Trial completion, Enrollment change, Trial primary completion date, Metastases:  Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma (clinicaltrials.gov) -  Mar 10, 2016   
    P2,  N=12, Completed, 
    N=113 --> 74 | Trial primary completion date: Jan 2016 --> Mar 2015 Active, not recruiting --> Completed | N=24 --> 12 | Trial primary completion date: Apr 2014 --> Jan 2014